Skip to content
DataLookout
Menu

ROXI-EVERESTNCT07626411

Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 66 → 84 locations
  2. Minor Trial sites expanded: 54 → 66 locations
  3. Minor Trial sites expanded: 45 → 54 locations
  4. Minor Trial sites expanded: 34 → 45 locations
  5. Minor Study sites: 32 to 34
  6. Notable Eligibility criteria expanded, about 12 words
    • Trial sites expanded: 8 → 32 locations
  7. Notable Recruitment opened
    • Trial sites expanded: 0 → 8 locations
    • Start date changed from estimate of Jul 31, 2026 to Aug 10, 2026
    v2
  8. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type) or systemic embolism
Timeframe: Approximately 36 months
Time to first occurrence of International Society on Thrombosis and Haemostasis (ISTH) major bleeding or ISTH Clinically Relevant Non-Major (CRNM) bleeding
Timeframe: Approximately 36 months

Secondary (14)

Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, ISTH major bleeding, or ISTH CRNM bleeding
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, or ISTH major bleeding
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, ISTH major bleeding, or all-cause death
Time to first occurrence of ISTH major bleeding
Time to first occurrence of hemorrhagic stroke, intracerebral hemorrhage, or hemorrhagic transformation of an ischemic stroke
Show 9 moreShow less
Time to occurrence of fatal bleeding
Number of ISTH major bleeding events
Number of ISTH CRNM bleeding events
Number of minor bleeding events
Time to all-cause death
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Severity of TEAEs
Occurrence of Anti-Drug Antibodies (ADA) to REGN7508
Magnitude of ADA to REGN7508

Arms and interventions

REGN7508 + PlaceboExperimental
Apixaban + PlaceboActive comparator

Drugs: REGN7508, Apixaban, Placebo

Sites

84 sites in 3 countries

United States 66, Japan 14, Canada 4